Product Name:1-(1H-imidazole-1-carbonyl)-1H-imidazole

IUPAC Name:1-(1H-imidazole-1-carbonyl)-1H-imidazole

CAS:530-62-1
Molecular Formula:C7H6N4O
Purity:98%
Catalog Number:CM104362
Molecular Weight:162.15

Packing Unit Available Stock Price($) Quantity
CM104362-1000g in stock ƈŤƥ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:530-62-1
Molecular Formula:C7H6N4O
Melting Point:-
Smiles Code:O=C(N1C=CN=C1)N1C=CN=C1
Density:
Catalog Number:CM104362
Molecular Weight:162.15
Boiling Point:394.6°C at 760 mmHg
MDL No:MFCD00005286
Storage:Protect from the light and Store in a dry place

Category Infos

Imidazoles
Imidazole is an important five-membered nitrogen-containing heterocyclic compound. Among the numerous heterocyclic compounds, imidazole and its derivatives are regarded as a unique and multifaceted scaffold material due to their diverse applications in industrial, organic and pharmaceutical chemistry. Imidazoles interact in different ways with many therapeutic targets, enzymes and receptors in biological systems and thus exhibit a wide range of biological activities. In particular, several imidazoles can be used as clinical drugs to treat various types of cancer with high therapeutic efficacy. Furthermore, imidazoles are one of the most critical segments in the field of anti-covid-19 virus drug discovery due to their ability to interact with active targets in living systems.
Imidazole Manufacturer
As a professional imidazole manufacturer, we can guarantee product quality and delivery time.our company has been committed to supply personalized product solutions to customers,pls consult us.

Column Infos

Cadisegliatin
vTv Therapeutics announces FDA submission for first phase 3 study of Cadisegliatin in patients with type 1 diabetes. Cadisegliatin (TTP399) is developed as an adjunctive therapy to insulin for the treatment of type 1 diabetes, and the phase 3 trial evaluates its safety and efficacy.
Glucokinase (GK) is mainly concentrated in liver cells, and involved in the regulation of glucose metabolism. Cadisegliatin (TTP399) is a liver-selective glucosekinase activator with a mechanism of action different from that of antidiabetic drugs. It binds to the allosteric site of GK and restores innate glucose-regulating capacity of the liver, not disrupting the interaction between GK and GKRP. Cadisegliatin previously received a Breakthrough Therapy designation from the U.S. FDA.